RA
AKBA icon

Royce & Associates’s Akebia Therapeutics AKBA Stock Holding History

Royce & Associates’s Portfolio AKBA Stock Details AKBA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-28,373
Closed -$39.4K – 752
2026
Q1 		$39.4K Buy
+28,373
New +$39K ﹤0.01% 773
2018
Q2 		– Sell
-537
Closed -$5K – 1215
2018
Q1 		$5K Buy
537
+190
+55% +$2.66K ﹤0.01% 1239
2017
Q4 		$5K Buy
347
+100
+40% +$1.66K ﹤0.01% 1234
2017
Q3 		$5K Buy
+247
New +$3.8K ﹤0.01% 1225

Other funds holding AKBA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $27.8B AUM 46.46% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Royce & Associates's AKBA Position: Q2 2026 in Review

Royce & Associates sold out of Akebia Therapeutics (AKBA) in Q2 2026, closing a stake of 28,373 shares — an estimated $39.4K sold.

Royce & Associates first reported a position in AKBA in Q3 2017 and held it in 4 quarters. The position peaked at $39.4K in Q1 2026. 170 funds tracked by Wall St. Rank hold AKBA as of Q2 2026.

  • Royce & Associates reported no remaining Akebia Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Royce & Associates sold 28,373 Akebia Therapeutics shares in Q2 2026, an estimated $39.4K.
  • Royce & Associates first reported a position in Akebia Therapeutics in Q3 2017 and held it in 4 quarters.
  • Royce & Associates's Akebia Therapeutics position peaked at $39.4K in Q1 2026.
  • 170 funds tracked by Wall St. Rank held Akebia Therapeutics as of Q2 2026.

Based on Royce & Associates's 13F filing for Q2 2026, filed 14 Aug 2026.